Cytokine derived treatment with reduced vascular leak syndrome
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Aug 2, 2022
Grant Date -
Mar 10, 2016
app pub date -
Apr 22, 2014
filing date -
Apr 19, 2013
priority date (Note) -
In Force
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an interleukin 15 (IL-15) derivative conjugate so as to induce a proliferation of natural killer cells (NK cells) which is the same or higher than the one obtained with high dose of interleukin-2 (HDIL-2); eventually associated with a pharmaceutically acceptable carrier.
First Claim
Other Claims data not available
Family
Loading Family data...
International Classification(s)
- 2014 Application Filing Year
- A61K Class
- 14144 Applications Filed
- 11600 Patents Issued To-Date
- 82.02 % Issued To-Date
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 3 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 3.5 Year Payment | $1600.00 | $800.00 | $400.00 | Feb 2, 2026 |
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Feb 2, 2030 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Feb 2, 2034 |
